Solus Advanced Materials Co., Ltd. (KRX:33637K)

Revance Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	96,400	155,065	129,050	162,773	139,588	305,602
Short-Term Investments	-	20,077	145,000	-0	-	30
Cash & Short-Term Investments	96,400	175,142	274,050	162,773	139,588	305,632
Cash Growth	-42.72%	-36.09%	68.36%	16.61%	-54.33%	222.92%
Accounts Receivable	-	117,017	58,341	90,798	77,370	55,605
Other Receivables	-	12,699	9,962	5,894	6,377	4,893
Receivables	-	129,784	68,378	96,834	83,862	60,627
Inventory	-	224,391	192,561	172,275	139,509	67,604
Prepaid Expenses	-	14,545	16,904	17,912	8,929	7,831
Other Current Assets	389,600	53,357	12,388	58,185	22,582	8,682
Total Current Assets	486,000	597,219	564,281	507,980	394,470	450,376
Property, Plant & Equipment	-	1,367,658	1,025,345	865,287	535,001	318,395
Long-Term Investments	-	20.71	8,947	2,424	-	-
Other Intangible Assets	-	11,477	15,604	19,149	17,099	8,670
Long-Term Deferred Tax Assets	-	74,021	63,609	49,776	52,151	46,537
Long-Term Deferred Charges	-	1,358	613	1,531	2,582	3,687
Other Long-Term Assets	1,514,600	27,452	28,204	14,432	9,924	13,033
Total Assets	2,000,600	2,079,395	1,706,722	1,461,040	1,011,600	841,168
Accounts Payable	-	59,404	46,078	60,482	78,385	51,249
Accrued Expenses	-	22,351	22,772	21,885	12,985	10,877
Short-Term Debt	-	335,274	209,181	172,988	140,160	58,739
Current Portion of Long-Term Debt	542,600	289,242	111,813	126,857	35,901	21,624
Current Portion of Leases	-	3,420	3,328	1,281	1,959	1,888
Current Income Taxes Payable	-	4,518	73,644	7,057	4,214	6,457
Current Unearned Revenue	-	-	-	-	1	2
Other Current Liabilities	243,100	109,402	101,192	31,592	18,989	16,591
Total Current Liabilities	785,700	823,611	568,008	422,142	292,593	167,427
Long-Term Debt	236,500	140,010	53,621	52,181	123,461	168,046
Long-Term Leases	-	18,615	20,590	3,325	3,621	4,957
Long-Term Unearned Revenue	-	11.7	21.9	-	-	-
Long-Term Deferred Tax Liabilities	-	135.39	180.79	305.37	60.24	5,452
Other Long-Term Liabilities	-	3,470	4,354	64,159	67,151	1,687
Total Liabilities	1,022,200	987,931	648,534	542,937	489,392	351,310
Common Stock	9,100	9,090	4,546	4,546	3,960	3,960
Additional Paid-In Capital	-	518,682	523,571	523,536	295,236	295,236
Retained Earnings	-	172,488	172,401	-10,538	4,773	-6,711
Treasury Stock	-	-37	-37	-36.71	-36.71	-36.71
Comprehensive Income & Other	969,300	71,976	32,338	27,895	-1,591	-288.66
Total Common Equity	978,400	772,200	732,819	545,402	302,341	292,159
Minority Interest	-	319,264	325,369	372,701	219,867	197,700
Shareholders' Equity	978,400	1,091,464	1,058,188	918,103	522,207	489,859
Total Liabilities & Equity	2,000,600	2,079,395	1,706,722	1,461,040	1,011,600	841,168
Total Debt	779,100	786,562	398,532	356,632	305,102	255,253
Net Cash (Debt)	-682,700	-611,420	-124,482	-193,859	-165,514	50,379
Net Cash Per Share	-7510.68	-7018.19	-1428.87	-2197.84	-2180.72	663.76
Filing Date Shares Outstanding	90.9	90.9	35.11	70.21	61.17	61.17
Total Common Shares Outstanding	90.9	90.9	90.9	70.21	75.9	75.9
Working Capital	-299,700	-226,392	-3,727	85,838	101,877	282,949
Book Value Per Share	10763.80	8495.30	8062.05	7767.90	3983.47	3849.32
Tangible Book Value	978,400	760,723	717,215	526,253	285,242	283,489
Tangible Book Value Per Share	10763.80	8369.04	7890.39	7495.17	3758.19	3735.09
Land	-	40,425	33,177	21,284	9,176	7,894
Buildings	-	497,011	403,118	387,309	143,484	170,168
Machinery	-	542,673	459,264	452,849	128,687	255,678
Construction In Progress	-	669,419	417,519	271,750	237,270	85,635

Source: S&P Global Market Intelligence. Standard template. Financial Sources.